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Abstract
Paul Ehrlich’s dream of a ‘magic bullet’ that would specifically destroy invading microbes is now a major aspect of
clinical medicine. However, a century later, the implementation of this medical holy grail continues being a
challenge in three main fronts: identifying the right molecular or cellular targets for a particular disease, having a
drug that is effective against it, and finding a strategy for the efficient delivery of sufficient amounts of the drug in
an active state exclusively to the selected targets. In a previous work, we engineered an immunoliposomal
nanovector for the targeted delivery of its contents exclusively to Plasmodium falciparum-infected red blood cells
[pRBCs]. In preliminary assays, the antimalarial drug chloroquine showed improved efficacy when delivered inside
immunoliposomes targeted with the pRBC-specific monoclonal antibody BM1234. Because difficulties in
determining the exact concentration of the drug due to its low amounts prevented an accurate estimation of the
nanovector performance, here, we have developed an HPLC-based method for the precise determination of the
concentrations in the liposomal preparations of chloroquine and of a second antimalarial drug, fosmidomycin. The
results obtained indicate that immunoliposome encapsulation of chloroquine and fosmidomycin improves by
tenfold the efficacy of antimalarial drugs. The targeting antibody used binds preferentially to pRBCs containing late
maturation stages of the parasite. In accordance with this observation, the best performing immunoliposomes are
those added to Plasmodium cultures having a larger number of late form-containing pRBCs. An average of five
antibody molecules per liposome significantly improves in cell cultures the performance of immunoliposomes over
non-functionalized liposomes as drug delivery vessels. Increasing the number of antibodies on the liposome
surface correspondingly increases performance, with a reduction of 50% parasitemia achieved with
immunoliposomes encapsulating 4 nM chloroquine and bearing an estimated 250 BM1234 units. The nanovector
prototype described here can be a valuable platform amenable to modification and improvement with the
objective of designing a nanostructure adequate to enter the preclinical pipeline as a new antimalarial therapy.
Keywords: antimalarial chemotherapy, chloroquine, fosmidomycin, half-antibodies, immunoliposomes, malaria,
nanomedicine, targeted drug delivery
Introduction
Malaria is an acute and/or chronic infection caused by
protozoans of the genus Plasmodium. Clinical manifes-
tations are fever, chills, prostration, and anemia, whereas
severe disease can include metabolic acidosis, cerebral
malaria, and multiorgan system failure, and coma and
death may ensue. More than 40% of the world’s
population lives with some risk of contracting malaria,
with most recent estimates suggesting several hundred
million clinical cases and 800,000 deaths each year [1,2],
of which the large majority are children below 5 years
[3,4]. The recent call for the elimination and eradication
of the disease requires research from multiple fronts,
including developing strategies for the efficient delivery
of new medicines [5]. Four species cause diseases in
humans: P. vivax, P. ovale, P. malariae, and P. falci-
parum, with the latter causing the most deadly and
severe cases. In the life cycle of Plasmodium parasites
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(for a review, see Tuteja [6]), the female Anopheles mos-
quito inoculates, during a bite, Plasmodium sporozoites
that bind to and infect hepatocytes and proliferate into
thousands of merozoites in the liver. Merozoites rupture
from the hepatocytes and invade red blood cells [RBCs],
where they develop first into rings and then into the
late forms, trophozoites and schizonts (Figure 1). Schi-
zont-infected RBCs burst and release more merozoites,
which start the blood cycle again. Because the blood-
stage infection is responsible for all symptoms and
pathologies of malaria, Plasmodium-infected RBCs
[pRBCs] are a main chemotherapeutic target [7].
The need to develop new strategies to treat malaria is
urgent if one considers that the cases of resistance to
current antimalarial agents increase, especially in zones
in which P. falciparum is endemic, and calls for com-
bined therapy approaches [5,8]. Several drugs show dif-
ferent degrees of toxicity, which limits their use because
current administration forms release the free compound
in the blood and offer little specificity regarding the tar-
geted cells [9]. Consequently, to achieve therapeutic
levels that extend over time, the initial concentration of
the drug in the body should be high. On the other
hand, if the administered chemical has unspecific toxi-
city, the low doses required contribute to the develop-
ment of resistant parasite strains [10]. The challenge of
drug delivery is the liberation of adequate doses of ther-
apeutic agents to a specific target site at the right time
in a safe and reproducible manner [11]. A number of
mechanisms can provide controlled release, including
transdermal patches, implants, inhalation systems,
bioadhesive systems, and nanoencapsulation [12-14], but
few of these have been designed for specificity. Taking
into account the peculiarities of pRBCs, lipid-based
nanocarriers have been one of the most promising
approaches for the targeted delivery of antimalarial
drugs [15].
Liposomes are synthetic lipid bilayer-enclosed struc-
tures up to several hundred nanometers in diameter
that can improve the delivery of bioactive molecules by
functioning as circulating microreservoirs for sustained
release [16,17]. Liposomes bearing cell-specific recogni-
tion ligands on their surfaces have been widely consid-
ered as drug carriers in therapy [18,19], and liposome
encapsulation has been assayed for the targeted delivery
of compounds against murine malaria [20-22]. Liposo-
mal nanovessels incorporating a P. berghei amino acid
sequence have been shown to greatly increase their tar-
geting to the liver [23,24], suggesting that they can be
an adequate vector to channel antimalarials towards the
hepatocyte stages of the parasite.
In a previous work [25], we engineered an immunoli-
posomal nanovector for the targeted delivery of its con-
tents exclusively to pRBCs. Two hundred-nanometer
liposomes loaded with quantum dots were covalently
functionalized with oriented, specific half-antibodies
against P. falciparum late form-infected pRBCs. In less
than 90 min, 100% of late form-containing pRBCs and
0% of noninfected RBCs in living P. falciparum cultures
were infiltrated by the content of targeted immunolipo-
somes. Here, we present a quantitative study of the effi-
cacy of this nanovector in ameliorating the activity of
the antimalarial drugs chloroquine and fosmidomycin,
and discuss its characteristics and room for improve-
ment regarding future animal assays that might place
this prototype on the threshold of clinical trials.
Figure 1 Giemsa staining of Plasmodium-infected RBCs. At the ring (A), trophozoite (B), and schizont (C) stages of P. falciparum.
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Materials and methods
Materials
Except where otherwise indicated, all reagents were pur-
chased from Sigma-Aldrich Corporation (St. Louis, MO,
USA). The commercial monoclonal antibody BM1234
against P. falciparum pRBCs was obtained from Acris
Antibodies GmbH (Herford, Germany).
Liposome and immunoliposome preparation
Liposomes were prepared by the lipid film hydration
method [26], with the lipid formulation 1,2-dioleoyl-sn-
glycero-3-phosphatidylcholine [DOPC] (Avanti Polar
Lipids, Inc., Alabaster, AL, USA)/cholesterol 80:20, as
described previously [25]. The dry lipids were hydrated
at 37°C in phosphate-buffered saline [PBS] containing
the antimalarial drug to obtain a concentration of 10
mM lipid. For the coupling of targeting antibodies to
liposomes, we followed established protocols [27] that
use 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-
N-[4-(p-maleimidophenyl)butyramide] [MPB-PE]
(Avanti Polar Lipids, Inc.) to incorporate proteins into
liposomes (DOPC/cholesterol/MPB-PE 77.5:20:2.5, 10
mM lipid) through the reaction of the maleimide group
in the lipid with a thiol group from the ligand [25].
Quantification of chloroquine and fosmidomycin
The amount of chloroquine and fosmidomycin encapsu-
lated inside liposomes was determined using high-per-
formance liquid chromatography with tandem mass
spectrometry [HPLC-MS/MS]. Prior to analysis, lipids
were extracted following stardard protocols [28] in
order to release the entrapped drug. Briefly, 100 μl of
liposome sample was mixed with 225 μl of cold metha-
nol and 125 μl of chloroform. Phase separation was
achieved by adding 125 μl of 0.1 M HCl and 125 μl of
chloroform. After mixing thoroughly, the samples were
spun down at 7,500 × g for 5 min. The upper water-
methanol layer, containing the drug that had been
encapsulated inside liposomes, was collected and stored
at -20°C until analysis. HPLC analysis was performed in
an Alliance 2695 chromatographic system (Waters Cor-
poration, Milford, MA, USA) using an Atlantis dC18
analytical column (internal diameter [i.d.] 150 × 2.1
mm, 5 μm, Waters Corporation) for chloroquine and a
Luna C18 analytical column (i.d. 150 × 2.0 mm, 5 μm,
Phenomenex, Torrance, CA, USA) for fosmidomycin,
with mobile phase A (0.2% formic acid in water) and B
(acetonitrile). The linear gradient for the determination
of chloroquine at a flow rate of 0.3 ml/min was (%
mobile phase B/min) 0/0, 10/2, 40/17, and 90/22
whereas for the determination of fosmidomycin at a
flow rate of 0.4 ml/min, it was 0/0, 0/5, and 95/10. The
HPLC system was coupled to a SCIEX API 365 Triple
Quadrupole mass spectrometer equipped with a Turbo
Ion Spray ion source (PerkinElmer, Waltham, MA,
USA). For quantification purposes, data were collected
in the multiple reaction monitoring mode with positive-
ion detection for chloroquine and negative-ion detection
for fosmidomycin, tracking the transition of the parent
and product ions specific for each compound: 320.3/
141.9 and 320.3/246.7 for chloroquine and 182.0/79.0
and 182.0/136.0 for fosmidomycin.
Cryo-electron microscopy
For cryo-electron microscopy analysis of the prepara-
tions of liposomes, a thin aqueous film was formed by
dipping a glow-discharged holey carbon grid in the lipo-
some suspension and then blotting the grid against a fil-
ter paper. The resulting thin sample films spanning the
grid holes were vitrified by plunging the grid (kept at
100% humidity and room temperature) into ethane,
which was maintained at its melting point with liquid
nitrogen, using a Vitrobot (FEI Company, Eindhoven,
The Netherlands). The vitreous films were transferred
to a Tecnai F20 transmission electron microscope
[TEM] (FEI Company) using a cryotransfer (Gatan, Inc.,
Pleasanton, CA, USA), and the samples were observed
in a low-dose mode. Images were acquired at 200 kV at
a temperature between -170°C and -175°C, using low-
dose imaging conditions not exceeding 20 e-/Å2, with a
4,096 × 4,096 pixel CCD Eagle camera (FEI Company),
and digitized with the Tecnai Image Acquisition
program.
Plasmodium falciparum cell culture and growth inhibition
assays
The P. falciparum 3D7 strain was grown in vitro in
group B washed human RBCs prepared as described
elsewhere [25] using previously described conditions
[29]. Briefly, parasites (thawed from glycerol stocks)
were cultured at 37°C in Petri dishes containing RBCs
in RPMI complete medium under a gas mixture of 92%
N2, 5% CO2, and 3% O2. Synchronized cultures were
obtained by 5% sorbitol lysis [30], and the medium was
changed every 2 days maintaining 3% hematocrit. For
culture maintenance, parasitemias were kept below 5%
late forms by dilution with washed RBCs. For standard
growth inhibition assays, parasitemia was adjusted to
1.5% with more than 90% of parasites at the ring stage
after sorbitol synchronization. For modified growth inhi-
bition assays, synchronized cultures were incubated for
24 h before addition of the drug to allow for the appear-
ance of late forms presenting the epitope recognized by
BM1234 bound to immunoliposomes. Two hundred
microliters of these living Plasmodium cultures were
plated in 96-well plates and incubated for 48 h at 37°C
Urbán et al. Nanoscale Research Letters 2011, 6:620
http://www.nanoscalereslett.com/content/6/1/620
Page 3 of 9
in the presence of free drugs and drugs encapsulated in
liposomes and immunoliposomes at a final concentra-
tion of 100 μM lipid. Parasitemia was determined by
microscopic counting of blood smears or by fluores-
cence-assisted cell sorting [FACS]. Smears were fixed in
methanol for a few seconds and then stained for 10 min
with Giemsa (Merck Chemicals, Darmstadt, Germany)
diluted 1:10 in Sorenson’s buffer, pH 7.2. After washing
with distilled water and drying, the ratio of the infected
vs. noninfected RBCs was determined by microscopic
analysis. For FACS analysis, noninfected RBCs and sam-
ples containing pRBCs were diluted to a final concentra-
tion of 1 to 10 × 106 cells/ml. The cell suspension was
stained with SYTO 11 (0.5 mM stock in DMSO, Mole-
cular Probes, Eugene, OR, USA) to a final concentration
of 0.5 μM, and samples were incubated for 5 to 10 min
prior to analysis in a Cytomics FC 500 MPL (Beckman
Coulter, Inc., Fullerton, CA, USA) set up with the stan-
dard configuration. Excitation of the sample was done
using a 488-nm, air-cooled, argon-ion laser at 15-mW
power using forward and side scatter to gate the RBC
population, and SYTO 11 green fluorescence (525 nm)
was collected in a logarithmic scale. The single-cell
population was selected on a forward-side scattergram,
and the green fluorescence from this population was
analyzed. Parasitemia was expressed as the number of
parasitized cells per 100 erythrocytes.
Statistical analysis
Data are presented as the mean ± standard error of at
least three independent experiments, and the corre-
sponding standard errors in histograms are represented
by error bars. Statistical analyses were performed using
the Statgraphics Centurion XVI.I data analysis and sta-
tistical software. The parametric Student’s t test was
used to compare two independent groups when data fol-
lowed a Gaussian distribution. Otherwise, the nonpara-
metric Mann-Whitney test was used. Differences were
considered significant when the p value was ≤ 0.05.
Confocal fluorescence microscopy
For immunofluorescence assays, pRBC smears were
fixed in ice for 2 min in acetone/methanol (90:10) and
incubated with 2 μg BM1234 monoclonal antibody/ml
PBS containing 0.75% w/v BSA for 90 min at 37°C.
After PBS washing steps, primary antibodies were
detected with a secondary fluorescent antibody Alexa
Fluor 488 goat anti-mouse F(ab’)2 (Molecular Probes).
Parasite nuclei were stained with 4’6-diamino-2-pheny-
lindole [DAPI] (Invitrogen Corporation, Carlsbad, CA,
USA) during the secondary antibody incubation, and the
RBC membrane was labeled with a wheat germ aggluti-
nin [WGA]-tetramethylrhodamine conjugate (Molecular
Probes). After the corresponding incubations and PBS
washing steps, the samples were finally mounted with
Mowiol (Calbiochem, Merck Chemicals) following stan-
dard protocols [31]. The samples were imaged with a
TCS SP5 laser scanning confocal microscope equipped
with an acoustic optical beam splitter (Leica Microsyt-
stems Inc., Buffalo Grove, IL, USA), a DMI6000 inverted
microscope (Leica Microsytstems Inc.), blue diode (405
nm), Ar (458/476/488/496/514 nm), diode-pumped
solid-state (561 nm), and HeNe (594/633 nm) lasers,
and APO ×63 oil (NA 1.4) or glycerol (NA 1.3) immer-
sion objective lenses. DAPI, Alexa Fluor 488, reflection
(for hemozoin detection), and WGA-rhodamine images
were acquired sequentially using 405, 488, 488, and 561
laser lines and emission detection ranges 415 to 480
nm, 500 to 550 nm, 480 to 500 nm, and 571 to 625 nm,
respectively, with the confocal pinhole set at 1 airy unit.
Bright field transmitted light images were acquired
simultaneously at 400 Hz in a 512 × 512 pixel format,
×8 zoom, and a pixel size of 60 × 60 nm.
Results and discussion
In preliminary in vitro assays, chloroquine showed an
improved efficacy as an antimalarial when delivered
inside targeted immunoliposomes [25]. However, diffi-
culties in determining the exact concentration of the
drug due to the low administered amounts prevented an
accurate estimation of the nanovector performance.
Here, we have established an HPLC method for the reli-
able quantification of chloroquine and fosmidomycin
with good linearity ranges of 0.1 to 100 ng/ml (Y =
0.0223X - 1.98 × 10-13, r2 = 0.9942) and 5 to 2,500 ng/
ml (Y = 246X, r2 = 0.9997), respectively (Figure 2). The
detection limits obtained have been 0.04 ppb for chloro-
quine and 1 ppb for fosmidomycin.
For immunoliposome assembly, different lipid combina-
tions had been tested in order to establish a formulation
with low hemolytic activity and low general cytotoxicity,
which is DOPC/cholesterol/MPB-PE 77.5:20:2.5 [25].
Liposomes formed in this way were stable and generally
did not coalesce even after high-speed centrifugation
(Figure 3A), but occasionally, fusion events were observed
(Figure 3B). Although dynamic light scattering analysis
indicated that the liposome population had a mean dia-
meter of 200 nm and a lower limit of 100 nm, TEM
images showed a significant number of smaller liposomes
down to 50 nm across. Most liposomes were unilamellar
but a substantial fraction of them (about 10%) were
enclosed by two or more lipid bilayers.
The targeting antibody BM1234 used in this work
is specific for pRBCs infected by the trophozoite and
schizont forms, but it does not bind significantly to
ring-stage pRBCs [25]. For this reason, we speculated
that a BM1234-mediated targeted delivery of immunoli-
posome-encapsulated drugs would be more efficient if
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administered to trophozoites rather than to rings. In a
classical Plasmodium growth inhibition assay, the drug
is added at the ring stage, and after 48 h of incubation
throughout a complete erythrocytic cycle, parasitemia is
determined. Here, we have also assayed the addition of
our targeted nanovectors at the trophozoite stage (24 h
later than in the standard protocol), determining parasi-
temia by FACS analysis and Giemsa-stained blood
smears after a further 48 h of incubation. The results
obtained (Figure 4A) show that in growth inhibition
assays performed 48 h after being administerd to pRBC
cultures, 2 nM chloroquine or 360 nM fosmidomycin in
solution reduces parasitemia by 3% to 6% when added
at either the ring or the trophozoite stage. Liposomal
chloroquine and fosmidomycin used at respective final
concentrations of 1.6 and 325 nM reduce parasitemia by
Figure 2 HPLC chromatograms showing the retention times of chloroquine and fosmidomycin extracted from immunoliposomes.
Figure 3 Cryo-TEM images of liposomes.
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Figure 4 Growth inhibition assays. (A) Effect on P. falciparum viability of chloroquine (CQ) and fosmidomycin (FM), free or encapsulated in
liposomes (L) or immunoliposomes (IL) and added at the ring or the trophozoite stage. The values express percentage of reduction respective
to the parasitemia of controls without drug added. Asterisks on top of individual bars indicate significant differences (p ≤ 0.05) in relation to the
corresponding control sample of the non-encapsulated drug. (B) Effect on P. falciparum viability of increasing amounts of BM1234 antibody on
chloroquine-containing immunoliposomes. The amount of chloroquine added to the culture was 4 nM in all samples. 1×, 10×, and 50 ×
correspond respectively to 5, 50, and 250 estimated antibody molecules per liposome. The asterisk indicates a significant difference (p ≤ 0.05).
(C) Grid showing the p values within the trophozoite and ring sample groups in the experiment from panel B. Bold numbers indicate a
significant difference (p ≤ 0.05).
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> 10% when added at the ring stage and by > 20% when
added at the trophozoite stage. The best results have
been obtained with chloroquine and fosmidomycin
encapsulated in immunoliposomes, which resulted in ca.
eightfold and fivefold improvement for encapsulated
drug concentrations 80% and 90% that of the free com-
pound, respectively. On an average, encapsulation in
immunoliposomes as described here improves drug effi-
cacy by an order of magnitude: similar drug amounts
kill 10 times more parasites if encapsulated, and 10
times less encapsulated drug eliminates approximately
the same number of parasites than the free compound:
when added at the trophozoite stage, 20 nM soluble
chloroquine kills 28.1 ± 0.6% of parasites vs. 26.5 ± 0.5%
for the immunoliposome-encapsulated drug at 1.6 nM
final concentration. The efficacy of the nanovector is
particularly relevant in the case of chloroquine, which
has an endogenous carrier across human erythrocyte
membranes that accumulates the drug selectively in
these cells [32]. As expected, because the targeting anti-
body used here does not recognize ring-infected pRBCs,
the efficacy of the immunoliposomes is much better
when administered at the trophozoite stage. This obser-
vation has clinical implications related with the syn-
chrony of falciparum malaria infection in humans,
namely the administration of such stage-specific nano-
vectors should be timed at the moment when the tar-
geted form is at its highest concentration in the blood.
Although this can be readily determined by FACS analy-
sis, Giemsa staining and a microscopic observation pro-
vide a more affordable way to quickly estimate the
intraerythrocytic phase of the infection.
We have calculated that the protocol used for the pre-
paration of the samples from Figure 4A results in an
average number of five antibody molecules per liposome
[25], and the data presented here indicate that this is
the minimal antibody/liposome ratio that significantly
improves the activity of immunoliposomal drugs. This
ratio was sufficient to provide a complete pRBC target-
ing specificity according to the delivery of immunolipo-
some-contained quantum dots [25], but the same
amount of targeting antibody in immunoliposomes does
not result in a 100% elimination of parasitemia at the
low antimalarial drug concentrations assayed. Because
the role of targeting antibodies is most likely to anchor
liposomes to pRBCs when a random collision occurs,
the in vitro efficacy of immunoliposomes as drug deliv-
ery vessels can likely be increased by incorporating
more antibodies on their surfaces. As shown in Figure
4B, C, increasing the antibody concentration in immu-
noliposomes containing 4 nM chloroquine results in a
corresponding significant increase of nanovector perfor-
mance, reaching a clearance of 50% parasitemia for
liposomes studded with an estimated 250 antibody
molecules. However, keeping the antibody concentration
as low as possible will contribute to reduce the immune
response towards plasma-circulating immunoliposomes.
Thus, when designing in vivo assays, a balance has to be
reached between a sufficiently high density of targeting
antibody for efficient drug delivery and levels below
those triggering fast lymphocyte uptake. Since another
factor affecting the number of random encounters
between liposomes and pRBCs is the movement of both
particles in solution, we expect that the turbulent mix-
ing in the bloodstream will permit the use of low target-
ing antibody amounts. As mentioned above, BM1234
immunoliposomes deliver their contents to all pRBCs
present in a sample, but when loaded with drug, they
are not able to eliminate all Plasmodium parasites. It is
possible that an increased performance can be achieved
even with a few targeting antibody molecules per lipo-
some if the amount of the encapsulated drug could be
increased. In this regard, Ashley et al. [33] have
assembled liposome-enclosed silica nanoparticles termed
protocells, able to carry high anticancer drug payloads,
with a single protocell having the capacity to kill a can-
cer cell. It would be worth exploring if such protocells
can also be used as antimalarial drug-containing
structures.
The preferential binding of BM1234 to trophozoites
and schizonts suggested a differential subcellular locali-
zation of the corresponding antigen throughout the
intraerythrocytic cycle of P. falciparum. This antibody
had been selected for its binding to external features of
pRBCs [25], which was a necessary condition for the
targeting of these cells in vivo. When pRBCs are fixed
with acetone/methanol prior to immunocytochemistry,
BM1234 is observed to bind internal pRBC structures
also (Figure 5). These are likely corresponding to
regions in the endomembrane system built by Plasmo-
dium that delineate the trafficking of the BM1234 anti-
gen from its synthesis towards its final location in the
pRBC plasma membrane. Alternatively, they could also
represent internalization routes of externally exposed
antigens. As expected, the subcellular localization of
BM1234 antigens is changing during the intraerythrocy-
tic cycle. A dominant spotted pattern in early tropho-
zoites (Figure 5A) is consistent with the binding to
pRBC intracellular membranous structures termed
Maurer’s clefts. In late trophozoites (Figure 5B) and
especially in schizonts (Figure 5C), BM1234 binds struc-
tures on the periphery of the pRBC.
The remarkable capacity of liposomes to inject their
contents into pRBCs presumably has its basis on altera-
tions of the pRBC plasma membrane, rendering it less
elastic and thus limiting the rebounding of colliding
liposomes. The resulting slightly longer interactions, a
phenomenon exacerbated if targeting antibodies are
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present, likely allow enough time for the physical phe-
nomenon of lipid bilayer fusion to occur. This hypoth-
esis could also explain why liposomes devoid of the
antibody do perform better when added at the tropho-
zoite stage since the membrane of ring-containing
pRBCs is more similar to uninfected erythrocytes than
that of pRBCs infected by later forms.
Conclusions
Next in our agenda is to advance towards a nanovector-
based antimalarial delivery strategy suitable to enter pre-
clinical trials. Liposomal nanovectors are adequate for a
parenteral delivery, indicated in cases of complicated
malaria, those at risk of developing severe disease, or if
the patient is vomiting and unable to take oral antimalar-
ials. Parenteral treatment can also be required in the last
mile of a malaria eradication protocol for the single-dose,
individualized administration of highly toxic drugs specifi-
cally targeted to pRBCs with good accuracy with the
objective of eliminating remaining multiresistant strains.
The nanovector prototype described here can improve
ca. tenfold the activity of hydrosoluble antimalarial drugs,
and it is amenable to improvement or adaptation through
modification of some of its parts, e.g., better antibodies or
targeting molecules, different nanocapsule structures, or
new antimalarial drugs. Finally, BM1234 immunolipo-
somes can also be an efficient drug delivery vessel for the
administration of liposoluble drugs against P. falciparum;
unlike chloroquine and fosmidomycin, the solubility of
hydrophobic compounds will be low when free in plasma,
but can be significantly increased when incorporated in
the lipid bilayers of liposomes.
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